PABHealth CareCompany Update22 Oct 202622 October 2026· 2 min read
Patrys Limited (ASX: PAB) Advances RLS-2202 Trial to Cohort 2
Patrys has advanced intravenous delirium candidate RLS-2202 into Cohort 2 after an acceptable initial safety review. The next cohort will compare its pharmacokinetics with oral quetiapine.